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The cystic ﬁbrosis transmembrane conductance regulator protein
(CFTR, ABCC7) is a unique member of the ABC protein family that
functions as a chloride channel. Deletion of amino acid residue F508, a
commonly occurringmutation in CFTR leads tomisfolding of the protein
and a reduction of the number and activity of CFTR channels at the cell
surface. Loss of CFTR function results in the lethal autosomal recessive
disease cysticﬁbrosis [1]. CFTR contains the normal four coredomains of
the ABC protein plus a hydrophilic regulatory (R) region (sometimes
considered to be a domain). The two core transmembrane domains
(TMDs) contribute to the formation of a chloride selective pore, and the
two core nucleotide binding domains (NBDs) bind and hydrolyse ATP to
regulate channel gating. Phosphorylation and dephosphorylation of the
R region controls channel activity [1,2]. Tobetterunderstand the context
of the F508del mutation within CFTR and the overall domain
organisation within the protein, structural data are needed.Structures of CFTR homologues have been published, [3–6], and
structural data for isolated CFTR domains (NBD1, NBD2, R region) are
available [7–9]—see the protein data bank ﬁle 3GD7 for the NBD2
structure. Expressed and puriﬁed in isolation, R region appears to have
properties characteristic of a disordered polypeptide [7] and is distinct
from the regulatory domains of bacterial ABC proteins [10], both in
terms of primary and tertiary structure. However, it is possible that
regulatory domains of ABC proteins may act in a similar fashion, by
inﬂuencing the dimerisation of the NBDs [7,10,11]. Medium resolution
data from 2D crystals of another member of the ‘C’ subclass of ABC
proteins have also been recently published [12]. Low-resolution
structural data from 2D crystals and single-particle analysis of the
whole CFTR protein have been reported. Interestingly, isolated CFTR
particles were observed to have a dimeric quaternary structure in all of
the single particle averaging studies [13–15], but the 2D crystals of CFTR
contained a single monomer in the unit cell [16]. Similarly, all X-ray
crystal structures of ABC transporters, so far, have revealed quaternary
structures equivalent to a single transporter (i.e., equivalent to a CFTR
monomer) [3,6,17–21], whilst studies of noncrystalline ABC transpor-
ters byEMhave reportedhigher levels of quaternary structure [22,23]. A
recent study [15] of unstained dimeric CFTR complexes by cryo-EM and
single-particle analysis revealed conformational changes induced by
channel activation conditions (R region phosphorylation and ATP
binding to the NBDs). The orientation of the monomers within the
dimeric complex was adjudged based on the docking of the Sav1866
transporter structure [4] within the CFTR density map. This work also
proposed plausible locations for the R region within CFTR based on the
differences between the CFTRmap and the Sav1866 homologue lacking
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been built on the basis of sequence alignments with the Sav1866 ABC
transporter [24,25], and modelling of the R region within CFTR was
attempted in one study [25].
The low-resolution structural data for CFTR were mostly consistent
with the X-ray crystal structures of CFTR homologues [3–6]; however,
one of the electron microscopy studies [14] reported a CFTR structure
with a smooth domed surface that contained large cavities, hence
implying a signiﬁcantly different tertiary structure for CFTRversus other
ABC proteins. Such a large change in conﬁguration versus other ABC
proteins would suggest that homology models for CFTR would need to
be revised considerably and would alter our understanding of its
channel properties. To resolve these discrepancies and to test the
accuracy of the CFTR homology models, we describe experiments using
a 1.8-nm-diameter Ni-NTA nanogold probe to label regions on the CFTR
protein. We show data for labelling of an internal hexa-Histidine
sequence in CFTR, as well as for the more conventional labelling of a C-
terminal Histidine puriﬁcation tag. These labelling data are comple-
mented by similar studies with a truncated CFTR protein that lacks the
entire NBD2 domain. Such labelling and domain removal approaches
have been widely used in structural studies and have located speciﬁc
sites, domains, and subunits successfully [13,26–33]. The nanogold
labellingmethod suffers froma relatively low labelling efﬁciency,which
may be due to a high dissociation rate of the probe [34,35], and we
describe an experimental strategy to overcome this limitation to the
methodology.
2. Materials and methods
2.1. CFTR expression and puriﬁcation
Internal hexa-His tags were inserted into the CFTR construct with
C-terminal deca-His tag at amino acids 696 and 890. A truncated CFTR
construct lacking the second NBD (CFTR-X1172) was generated as
described in Cui et al. [36]. The constructs were overexpressed in baby
hamster kidney-21 (BHK-21) cells as described earlier [16]. Cell
membranes were solubilised in dodecyl maltoside. The protein was
puriﬁed according to methods described in Rosenberg et al. [16] but
with a further chromatographic step using a Superdex 200 10/300
size-exclusion column [37].
2.2. Ni-NTA nanogold labelling of CFTR
CFTR protein (wild type or other constructs) and Ni-NTA nanogold
(Nanoprobes Inc.) at 1:10 molar ratio were incubated together for
3 hours at room temperature. Excess Ni-NTA nanogoldwas removed by
centrifugationat3000×g for 15 minusinga0.5-ml spin column(50 kDa
cutoff) (Millipore).
2.3. Negative staining
Samples were incubated for 20 s with glow-discharged carbon-
coated grids (400 mesh/in; Agar Scientiﬁc) and then blotted and
transferred to a droplet of 4% (wt./vol.) uranyl acetate for 1 min beforeTable 1
Image processing data for the data sets of negatively stained CFTR isolated in the presence
CFTR Ni-NTA gold CFTR
Calibrated pixel size at the specimen level (Å) 3.6 3.6
Box size (pixels) 64×64 80×80
Number of particles 4046 4412
Mask radius (Å) 90 90
Final resolution cutoff (low-pass ﬁlter, Å−1) 0.056 0.067
Resolution limit of ﬁnal structure (FSC=0.5, Å−1) 0.048 0.050
Angle used for 3D reﬁnement. 11.2o 11.0oblotting dry. Gridswere examinedwith a Philips Tecnai 10 transmission
electron microscope. Images were recorded on Kodak SO-163 ﬁlm or
Kodak 4489 ﬁlm for Ni-NTA nanogold labelled specimens,withminimal
underfocus employed to optimise the imaging of the 1.8-nm-diameter
gold spheres. Micrographs were developed for 1 min in full-strength
Kodak D19 developer.
2.4. Image processing
Filmswere digitised using a UMAXPowerLook 3000 scanner. A pixel
size of 3.6 Å/pixel or 4.8 Å/pixel was used. Image processing and 3D
reconstruction were carried out using the EMAN software suite [38].
Single particles were interactively selected manually. The contrast
transfer function (CTF) was corrected using the ‘ctﬁt’ program in the
EMAN suite [38]. After correction, a high-pass ﬁlter of 1/200 Å−1 was
applied to remove low frequency informationand also low-pass-ﬁltered
to a cut-off resolution of 1/20 Å−1. After reference-free class averages
were generated, the angular orientations of the characteristic views
were determined using a Fourier common-lines routine [39]. A
preliminary 3D density map was calculated by back-projecting the
class averages [40]. Iterative reﬁnement was carried out against the
preliminary structure. Convergence was judged to be achieved when
the Fourier Shell Correlation (FSC) curve between successive iterations
of the reﬁnement ceased to improve. The ﬁnal 3D maps were viewed
using XtalView [41] or Chimera [42]. Further details on the image
processing are given in Table 1.
3. Results
3.1. Puriﬁcation and homogeneity of CFTR
Various human CFTR constructs, all with a C-terminal deca-His tag
were overexpressed in baby hamster kidney 21 (BHK-21) cells, and the
membranes were solubilised in dodecyl maltoside according to
methods described in Rosenberg et al. [16]. Subsequent puriﬁcation
included two steps: (i) immobilised metal (Co2+-Talon) afﬁnity
chromatography with elution with 400 mM imidazole and (ii) wheat
germ lectin-agarose (WGA) chromatography with elution with 0.5 M
N-acetylglucosamine (GlcNAc). A relatively pure CFTR preparation was
thus obtained, as judged by SDS–PAGE and Coomassie blue staining
(Supplementary Fig. 1). However, electron microscopy of negatively
stained specimens of the puriﬁed material (Fig. 1A), identiﬁed
inhomogeneity arising from protein aggregates 20–40 nm in diameter.
The majority of these aggregates appeared to be amorphous; however,
in some CFTR preparations, we also observed circular aggregates
~20 nm in diameter (Fig. 1B) that appeared to have an octameric
quaternary structure. Similar ring-shaped structures have been
observed in preparations of the bacterial ABC transporter BmrA [22].
To improve the monodispersity of the preparations, a size exclusion
chromatography (SEC) step was applied, yielding more homogeneous
ﬁelds of negatively stained particles ~10 to 12 nm in diameter
(Fig. 1C). A weak interaction between CFTR and the Superdex column
matrix resulted in a retarded elution time, but a symmetrical peak was
nevertheless observed (data not shown). Previous studies using nativeof DDM.
Ni-NTA gold 696-His CFTR Ni-NTA gold 890-His CFTR CFTR-X1172
4.64 3.24 3.6
48×48 64×64 64×64
2493 3210 2444
97.4 97.2 90
0.090 0.056 0.056
0.038 0.043 0.048
12.5o 13.8o 13.8o
A CB
Fig. 1. (A&B) A ﬁeld of CFTR particles before SEC showing (in order of abundance) 10- to 12-nm-diameter particles (black arrows), amorphous aggregates of 20–40 nm (circles, white
arrows, panel A) and, in some preparations (panel B), cartwheel-shaped complexes (white arrows, circles). (C) After SEC, the 10- to 12-nm-diameter particles predominate giving a
homogeneous ﬁeld of stain-excluding particles (black arrows). The scale bars in each panel indicate 50 nm.
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composed of dimeric CFTR complexes that can be dissociated into
monomers under various conditions [15,43–45].
3.2. Structural studies of negatively stained CFTR dimeric complexes and
localization of CFTR domains
After SEC, negatively stained CFTR preparations showed uniform
10- to 12-nm-diameter particles (Fig. 1C), suggesting that single-
particle image processing procedures could be applied to generate
low-resolution 3D structural data for the protein [38]. Table 1
summarizes 3D structural data obtained for the various CFTR
constructs studied. Three of the constructs were probed by labelling
with 1.8-nm-diameter Ni-NTA nanogold spheres [30,31] before
negative staining (Fig. 2A) and subsequent single-particle analysis.
Removal of unbound gold particles was carried out using ultraﬁltra-
tionwith a 50-kDa cutoff membrane. Electronmicroscopywas used to
conﬁrm that the ultraﬁltration step was effective (Fig. 2B). Labelling
frequency was about 2–10% of the particles present, for the CFTR
constructs under study. Low-frequency and variable labelling has
been observed in other studies with this Ni-NTA nanogold probe
[13,26–28,30,31] and is probably due to steric restriction of gold
sphere binding as well as a relatively high off-rate for the probe, as
reported by Lata et al. [34,35]. Labelling efﬁciency of 2–10% is not an
insurmountable problem for the single-particle approach, sinceA B
Fig. 2. (A) Electron micrograph of negatively-stained CFTR single particles labelled with 1.8
dots whereas the protein particles are white. A few larger colloidal gold spheres are identiﬁ
(B) Electron micrograph of the ﬁltrate after ﬁltering the Ni-NTA nanogold-labelled CFTR sam
observed as well as uncomplexed gold particles and clusters of gold spheres (arrowheads).selection of labelled versus unlabelled particles is possible as the
gold spheres are readily identiﬁable in electron micrographs.
However, in the resultant data sets, selected particles display mostly
a single gold sphere, introducing asymmetry into oligomeric com-
plexes [26,27]. We therefore generated structures with C2 symmetry
or no symmetry (C1) for gold-labelled CFTR. The 3D structures
generated without symmetry were noisier and at lower resolution
than the corresponding structures generated with C2 symmetry
(Table 1); however, they were of similar size and shape, and two
copies of an atomic model of an ABC protein (Sav1866) could be ﬁtted
into the low-resolution envelope of the CFTR structure, giving further
justiﬁcation for the application of C2 symmetry.
The low-resolution C2-symmetrised structures of CFTR are shown in
Fig. 3. A comparison of full length CFTR before and after nanogold
labelling is shown in Fig. 3A. Both structures are superﬁcially similar in
size and shape, especially on one side of the complex (uppermost in the
panel). This upper side of the particle appears relatively featureless.
However, on the opposite side of the complex, features are better
deﬁned, and there are signiﬁcant differences caused by the gold
labelling (yellow spheres), which is restricted to this region. The strong
‘negative’ density of the gold label averages over a ~3-nm-diameter
region, causing deﬁcits in the nearby protein density, which is stain-
excluding and hence ‘positive’. The deﬁcits around the central position
of the gold label can best be observed in the ‘bottom’ view in Fig. 3A. The
smearing of the negative density of the gold sphere over a larger regionnm-diameter Ni-NTA-nanogold spheres . The gold spheres appear as small dark black
able (arrows), but the overall size distribution of the gold spheres is relatively narrow.
ple through a 50-kDa cutoff ultraﬁltration device. Small stain-excluding particles can be
The scale bars correspond to 50 nm.
90
5nm 5nm
A B
5nm
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C
Fig. 3. 3D structures and putative location of domains in CFTR dimeric particles: (A) Comparison of CFTR (grey, transparent surface) and nanogold-labelled CFTR (purple, yellow).
Top panel shows a side view. Bottom panel shows the bottom halves of the structures after a rotation as indicated. Averaged locations of the C-terminal gold labels (yellow surface,
green arrows) are indicated. The strong density of the gold label, which is the opposite of the stain-excluding protein density, gives the impression of a cavity around the gold. The
yellow surfaces are displayed at−10σ, grey and purple at +2σ below/above the mean density level. (B) Comparison of nanogold-labelled CFTR (purple/yellow surfaces as in panel
A) with the nanogold-labelled CFTR-890His construct (green, yellow surfaces). The gold spheres show a similar location in both structures. (C) Comparison of CFTR (grey,
transparent surface) with the nanogold-labelled CFTR-696His construct (blue, yellow). Locations of the C-terminal gold label and the 696 gold label are indicated (red arrows). The
yellow surfaces are at−4σ, blue and grey at +2σ. (D) Comparison of the low-resolution 3D structures of negatively stained CFTR (yellow, transparent surface) and the CFTR-X1172
construct (blue). Additional density in the putative NBD region (red arrows) is observed for the full-length CFTR structure. Some additional differences can be discerned in this view,
which may be rearrangements in location of NBD1 due to the lack of NBD2 in CFTR-X1172. The surfaces are rendered at +2σ above the mean density.
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of factors: (i) some ﬂexibility of the C-terminal His-tag, (ii) inherent
spread of gold particle sizes, and (iii) lower resolution of the 3D
structures (~2.5 nm) versus the size of the tag. The location of the Ni-
NTA nanogold label in the lower half of the 3D structure permits its
assignment as the cytoplasmic half of the particle since the C-terminus
has a cytoplasmic location [46]. In comparison to the unlabelled
structure, the gold sphere is intimately associated with the NBDs rather
than bound on, or outside, the outer surface. This may support the idea
for a functional role of the C-terminus in the C branch of the ABC family
[47,48], of which CFTR is a member.
3.3. Ni-NTA nanogold labelling of internal hexa-Histidine tags in CFTR.
We also attempted to extend the gold-labelling work by inserting
additional (internal) hexa-Histidine sequences into regions of CFTR
adjudged to be surface-exposed and sufﬁciently ﬂexible to provide a
likely binding site for the Ni-NTA nanogold probes. Two constructs
were generated, one with the hexa-His sequence starting at position
696 in the regulatory, R region of CFTR, the other at position 890 in the
fourth extracellular loop, which also contains consensus N-glycosyl-
ation sites. These constructs were expressed and puriﬁed as before,
and EM of the material after SEC demonstrated that the sample
homogeneity was equivalent to the original construct of CFTR. As
before, gold labelling frequency was found to be low, with a relatively
small proportion of multiply labelled particles. These constructs also
contained the deca-His C-terminal tag; hence, there were four
potential binding sites for the Ni-NTA nanogold probe in the dimeric
particles.
Labeling of the 890-His CFTR construct and structural analysis as
above resulted in the generation of a 3D structure that showed well-
deﬁned gold locations, but only one gold sphere was detected per
monomer corresponding to the position identiﬁed earlier as due to
the C-terminal deca-His tag (Fig. 3B). This maymean that position 890
in the fourth extracellular loop is sterically occluded from the gold
label, or perhaps that the local environment (e.g., nearby charged
residues) could modulate the afﬁnity of the hexa-His tag for the Ni2+
ion in the NTA nanogold probe. Although the labelling of the 890-His
tag was unsuccessful, the reproducibility of the labelling of the C-terminal deca-His tag in this construct builds conﬁdence in the
nanogold labelling and single-particle methodology.
The 3D structure of the Nanogold-labelled 696-His CFTR construct is
comparedwith the unlabelled CFTR structure in Fig. 3C. In this case, two
sites of labelling per monomer appeared in the negative regions of the
density map (red arrows, Fig. 3C). Although density at all labelling sites
was somewhat smeared compared to the earlier studies, the appearance
of a second site implied that this could be the averaged location of
position 696 in the R region of CFTR. If this assumption is correct, then
this region is close to the intracytoplasmic loops (ICLs) of the TMDs and
could potentially interact with the inner surface of the plasma
membrane. A previous comparison of the low-resolution structure of
CFTR with a bacterial homologue lacking the R region, Sav1866 [15],
shows a region of additional mass in CFTR around the surface of the
NBDs and ICLs. Consistent with this hypothesis, evidence from Ni-NTA
nanogold labelling suggested that the region around residue696 in theR
domain could lie near the ICLs.
3.4. Identiﬁcation of NBD2
Cui et al. [36] have shown that NBD2 in CFTR can be completely
removed without signiﬁcant loss of expression and maturation of the
protein [36]. Moreover, the truncated CFTR displays ATP-gated channel
activity, albeit with altered properties compared to the full-length
protein [36]. We puriﬁed and then generated a low-resolution 3D
structure for the CFTR-X1172 construct lacking NBD2. This structure is
shown in Fig. 3Dand is comparedwith the structure for full-lengthCFTR.
Although the two 3D structures are very similar on the featureless side
of the complex (uppermost in Fig. 3D), on the cytoplasmic side, there are
major differences, with two completely missing regions in the CFTR-
X1172 structure (Fig. 3D, red arrows). We therefore expect that the
missing regions correspond to NBD2 in the full-length CFTR structure,
whilst the domain common to both corresponds to NBD1. To further
explore this hypothesis, we generated a difference map by subtracting
the CFTR-X1172 3D map from the corresponding structure for full-
length CFTR. As shown in Fig. 4, the difference map shows signiﬁcant
positive density only on one side of the complex, with one major
ellipsoidal region of density and one small peripheral density per
monomer. The latter small region of density in the difference map may
Fig. 4. (A) Side view (left) and bottom view (right) of the CFTR-X1172 construct (grey density) and the full-length CFTR (purple density) superimposed with the calculated
difference map (cyan density). A large difference density can be observed (dashed box, centre). A NBD2 homology model can be automatically ﬁtted into the difference density
(zoomed region, right), although the limited resolution only allows partial orientation of the NBD model. The rest of the protein density is almost identical in the two maps at this
resolution. Scale bar is equal to 20 Å.
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in the CFTR-X1172 construct, but the larger ellipsoidal region directly
superimposes with the position of a domain in the full-length CFTR
structure. Fitting of a single NBD monomer [8] into this difference map
also shows that the overall shape and dimensions of the region would
match the expected envelope of NBD2 (Fig. 4, inset).
4. Discussion
In the experiments described in this article, we attempted to locate
individual domains in the low-resolution 3Ddensitymaps of full-length
CFTR protein. NBD2 and the C-terminus of the protein appear to be in
the same (lower) half of the protein density, as expected. NBD1 is
hypothesised to be the major density in this region that remains after
removal of NBD2. Perhaps surprisingly, removal of NBD2 appears to
have only a minor effect on the rest of the CFTR dimer. There is some
evidence fromthese studies for aminor rearrangement in theposition of
NBD1, but the TMDs appear to be relatively unaffected by the truncation
of the protein (Fig. 4). These structural data concur with the functional
measurements on the CFTR-X1172 construct which found that the
protein retained many aspects of its normal behaviour [36].
If the assignmentswepropose are correct, thenNBD1would seem to
be the ~4-nm-diameter domain located furthest away from the twofold
symmetry axis of the dimer (Figs. 3 and 4). NBD1 also appears to make
more contact with NBD2 from the other molecule of the dimer rather
than its cognate NBD2, which is somewhat unexpected, but may reﬂect
an inward-facing conformation of the protein, with separation of the
NBDs in eachmonomer. Such an arrangement has been observed in the
absence of nucleotide with other ABC proteins [3,12,17,49]. Residues
around amino acid 696 in CFTR lie close (within 10–20 residues) to the
end of NBD1 and the start of R region [8,50]. Somewhat unexpectedly,
Ni-NTA nanogold labelling of the 696 hexa-His construct indicated that
the additional gold spherewas, on average, close to the intracytoplasmic
loops—i.e., in a position between the TMDs and NBDs. A smeared, but
nevertheless identiﬁable, density for the gold label assumed to bind
close to the region around amino acid residue 696 in CFTR provides
some evidence that the R region interacts with the rest of the protein, at
least in the nonphosphorylated state. Data on isolated domains imply
that phosphorylation of the R region signiﬁcantly reduces its interaction
with NBD1 [7].
The C-terminal tail of CFTR is an extension of 20- to 40-amino acid
residues from the end of NBD2. This portion of the protein is
somewhat different compared to other ABC proteins, and in CFTR, it
contains a PDZ-binding consensus motif (−DTRL) [51–56]. The
Nanogold labelling of a C-terminal deca-Histidine puriﬁcation tag
provided evidence that it was located on the cytoplasmic side (as
expected) and roughly between the NBD1 and NBD2 domains of eachCFTRmonomer. Such a location implies functional signiﬁcance for this
region of the protein, since the formation of an NBD1–NBD2 sandwich
dimer (presumably with the exclusion of the C-terminal residues) has
been associated with conformational rearrangements in ABC proteins
and in CFTR in particular, with activation and the opening of the
chloride channel [57,58]. These observations might also suggest a way
in which PDZ-binding proteins such as NHERF might inﬂuence the
activity of CFTR in vivo [52,59].
The data presented here suggest that current homology models for
CFTR [24,25,60,61] based on other ATP-binding cassette proteins appear
to be reasonable, at least at a resolution sufﬁcient to resolve the major
core domains of the protein. An earlier study of negatively stained CFTR
dimers, however, was not consistent with such homology models, and
core domains were not resolved [14]. It is possible that the relatively
hollow CFTR reconstruction generated by Mio et al. [14] was due to a
combination of shallow staining (with therefore little internal detail
resolved), combined with the suppression of the amplitude of low-
frequency components in the images due to insufﬁcient correction of
the contrast transfer function [62].
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamem.2010.08.012.
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